Is CRIS or DNA more undervalued in 2026?

CirclFi compares Curis, Inc. (CRIS) and Ginkgo Bioworks Holdings, Inc. (DNA) using 13 institutional-grade valuation models. CRIS has a Quality of Company score of 5.0/10 while DNA scores 6.1/10.

Which is a better buy — CRIS or DNA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do CRIS and DNA valuations compare?

CRIS at $0.57 and DNA at $9.37 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

CRIS vs DNA Valuation Comparison 2026 — Intrinsic Value Analysis

CRIS

Biological Products, (No Diagnostic Substances)

Curis, Inc.

Quality

5.0

out of 10

Value Trap

LOW

Price

$0.57

Last close

Models

9/13

Active

DNA

Biological Products, (No Diagnostic Substances)

Ginkgo Bioworks Holdings, Inc.

Quality

6.1

out of 10

Value Trap

SAFE

Price

$9.37

Last close

Models

10/13

Active

Model-by-Model Comparison

Model	Type	CRIS Fair Value	CRIS Upside	DNA Fair Value	DNA Upside
Bayesian DCF	Intrinsic	$0.25	-56.7%	$0.13	-98.6%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$0.33	-41.9%	$0.12	-98.6%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$2.78	+389.6%	$3.29	-64.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for CRIS vs DNA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

CRIS vs DNA — Which Stock Is More Undervalued?

DNA scores higher with a 6.1/10 quality rating vs CRIS's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Curis, Inc. (CRIS) and Ginkgo Bioworks Holdings, Inc. (DNA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

CRIS currently trades at $0.57 with a QOC of 5.0/10, while DNA trades at $9.37 with a QOC of 6.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).